Reduced Drug Duty to Improve Cancer Care

Representation image

To enhance access to essential treatments and reduce financial strain on patients, the budget has removed customs duty on three cancer medications. The drugs – trastuzumab deruxtecan, osimertinib, and durvalumab previously had a 10% duty.

In 2023, the cancer medication Keytruda, produced by Merck, was also exempted from customs duty. There has been a long-standing demand to eliminate import duties on drugs for rare and critical diseases.

As reported by msn.com, typically, medicines are subject to a 10% basic customs duty, while certain life-saving drugs and vaccines either benefit from a reduced rate of 5% or are fully exempt from duties.

Also Read |  Zydus Partners with CSIR-CDRI to Develop Treatment for CKD-Induced Osteoporosis